Enoticumab
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively[1].
Product Specifications
CAS Number
[1192578-27-0]
Product Name Alternative
REGN421
UNSPSC
12352203
Target
Notch
Type
Inhibitory Antibodies
Related Pathways
Neuronal Signaling; Stem Cell/Wnt
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Cancer; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/enoticumab.html
Purity
99.64
Solubility
10 mM in DMSO
Smiles
[Enoticumab]
Molecular Weight
(146.48 kDa)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Smad2 (Mothers Against Decapentaplegic Homolog 2, Mothers Against DPP Homolog 2, MAD Homolog 2, Mad-related Protein 2, hMAD-2, SMAD Family Member 2, SMAD 2, hSMAD2, JV18-1, MADR2, MADH2) (FITC) discontinued
Human SIGLEC15 / Sialic acid-binding Ig-like lectin 15 ELISA Kit
Human SIGLEC15 / Sialic acid-binding Ig-like lectin 15 ELISA Kit
Human SIGLEC15 / Sialic acid-binding Ig-like lectin 15 ELISA Kit
Human SIGLEC15 / Sialic acid-binding Ig-like lectin 15 ELISA Kit